期刊文献+

血清NSE、TSGF、FERR及CA125联合检测对卵巢癌的诊断价值 被引量:12

Diagnostic value of combined detection of serum NSE,TSGF,FERR and CA125 in ovarian cancer
下载PDF
导出
摘要 目的:探讨血清神经元特异性烯醇化酶(neuron-specific enolase,NSE)、恶性肿瘤特异生长因子(tumor specific growth factor,TSGF)、铁蛋白(Ferritin,FERR)及糖类抗原125(carbohydrate antigen125,CA125)4种血清肿瘤标志物联合检测对卵巢癌的诊断价值。方法:选取2018年3月至2020年3月青海省第五人民医院收治的50例卵巢癌患者作为卵巢癌组,43例卵巢良性病变患者作为良性病变组,选取同期37例健康体检女性患者作为对照组。检测3组血清TSGF、CA125、NSE及FERR水平,评价各血清肿瘤标志物的敏感度和特异度;采用ROC曲线分析TSGF、CA125、NSE及FERR 4项肿瘤标志物联合检测对卵巢癌的诊断价值。结果:卵巢癌组患者血清肿瘤标志物TSGF、CA125、NSE及FERR水平均高于对照组及良性病变组,差异均有统计学意义(P<0.05);卵巢癌组TSGF、CA125、NSE及FERR 4种血清肿瘤标志物单项检测阳性率均高于良性病变组及对照组,差异均有统计学意义(P<0.05);4种血清肿瘤标志物联合检测阳性率为82.0%均高于任一单项肿瘤标志物检测阳性值,差异有统计学意义(P<0.05);4种肿瘤标志物联合检测对卵巢癌的诊断曲线下面积为0.913,敏感度为82%,特异度为81.40%,敏感度和曲线下面积均高于4项血清肿瘤指标单独检测的诊断价值。结论:CA125、CEA、NSE及TSGF联合检测能明显提高卵巢癌诊断的灵敏度和准确度,其诊断价值高于单一肿瘤标志物检测。 Objective:To investigate the diagnostic value of combined detection of serum neuron-specific enolase(NSE),malignant tumor-specific growth factor(TSGF),ferritin(FERR)and carbohydrate antigen 125(CA125)in ovarian cancer.Methods:From March 2018 to March 2020,50 patients with ovarian cancer admitted to our hospital were selected as the ovarian cancer group,43 patients with benign ovarian lesion as the benign lesions group,and 37 healthy female patients in the same period were selected as the control group.Detect three groups of serum TSGF,CA125,NSE,FERR levels to evaluate the sensitivity and specificity of each serum tumor marker;use ROC curve to analyze TSGF,CA125,NSE,FERR and the combined detection of four tumor markers for the diagnosis value of ovarian cancer.Results:The serum tumor markers TSGF,CA125,NSE and FERR levels in the ovarian cancer group were higher than those in the control group and the benign lesion group,and the differences were statistically significant(P<0.05);the positive rate of single detection of TSGF,CA125,NSE and FERR in the ovarian cancer group was higher than that in the benign lesion group and the control group,the difference was statistically significant(P<0.05);the positive rate of combined detection of 4 serum tumor markers was 82.0%,which was higher than that of any single tumor and the difference was statistically significant(P<0.05);the area under the curve for the diagnosis of ovarian cancer by the combined detection of four tumor markers was 0.913,with the sensitivity of 82%and the specificity of 81.40%,and the sensitivity and the area under the curve were higher than those of the four serum tumor indicators separately detected.Conclusion:The combined detection of CA125,CEA,NSE and TSGF can significantly improve the sensitivity and accuracy of ovarian cancer diagnosis,and its diagnostic value is higher than that of single tumor marker detection.
作者 祁慧兰 李鑫 王春兰 QI Huilan;LI Xin;WANG Chunlan(Department of Laboratory Medicine,Qinghai Provincial Fifth People’s Hospital,Xining 810007,China)
出处 《临床与病理杂志》 CAS 2021年第10期2254-2259,共6页 Journal of Clinical and Pathological Research
基金 青海省第五人民医院青年科学基金(2017-Y-02)。
关键词 卵巢癌 肿瘤标志物 联合检测 诊断价值 ovarian cancer tumor markers combined detection diagnostic value
  • 相关文献

参考文献10

二级参考文献119

  • 1李巍,崔恒,冯捷,李艺.卵巢癌诊断的研究进展[J].中华妇产科杂志,2005,40(7):496-498. 被引量:74
  • 2全国肿瘤登记中心.中国肿瘤登记工作指导手册[M].北京:中国协和医科大学出版社,2004.48-50.
  • 3Adamson GD, Pasta DJ. Endometriosis fertility index: the new, validated endometriosis staging system [ J ]. Fertil Ster- il,2010,94(5) : 1609-1615.
  • 4Bulun SE,Utsunomiya H, Lin Z, et al.Steroidogenic factor- 1 and endometriosis [ J ].Mol Cell Endocfinol, 2009,300 ( 1 - 2) :104-108.
  • 5Tito SP,Roberto B,Salvatore G, et al. CA125 serum values in surgically treated endometriosis patients and its relation- ships with anatomic sites of endometriosis and pregnancy rate [ J]. Fertil Steril, 2010, 95(1) :393-396.
  • 6American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. Committee Opinion No. 477: the role of the obstetrician- gynecologist in the early detection of epithelial ovarian cancer[ J ]. Obstet Gyneeol, 2011,117 ( 3 ) : 742-746.
  • 7MUNKARAH A, CHATYERJEE M, TAINSKY MA. Update on ovarian cancer screening [ J ]. Curr OpinObstet Gyneco1,2007,19 ( 1 ) : 22-26.
  • 8BUYS SS, PARTRIDGE E, BLACK A, et al. Effect of screening on ovarian cancer mortality: The prostate, lung, colorectal and ovarian (PLCO) cancer screening pandomized controlled trial [ J ]. JAMA, 2011,305 (22) :2295-2303.
  • 9BALDWIN LM,TRIVERS KF, MATrHEWS B, et al. Vignette-based study of ovarian cancer screening: do U.S. physicians report adhering to evidence-based recommendations [ J ] Ann Intern Med, 2012, 156(3) :182-194.
  • 10BAST RC JR,XU FJ,YU YH,et al. CA 125: the past and the future[ JJ. Int J Biol Markers, 1998,13 (4) :179-187.

共引文献398

同被引文献115

引证文献12

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部